img

Global Immunotherapy Drugs for Neuroblastoma Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Immunotherapy Drugs for Neuroblastoma Market Research Report 2024

Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
According to Mr Accuracy reports’s new survey, global Immunotherapy Drugs for Neuroblastoma market is projected to reach US$ 63 million in 2034, increasing from US$ 45 million in 2024, with the CAGR of 4.6% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Immunotherapy Drugs for Neuroblastoma market research.
Key manufacturers engaged in the Immunotherapy Drugs for Neuroblastoma industry include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of Immunotherapy Drugs for Neuroblastoma were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Immunotherapy Drugs for Neuroblastoma market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Immunotherapy Drugs for Neuroblastoma market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals
Segment by Type
Dinutuximab
Naxitamab
Other

Segment by Application


Hospital
Clinic
Other

Consumption by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Immunotherapy Drugs for Neuroblastoma report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Immunotherapy Drugs for Neuroblastoma Market Overview
1.1 Product Overview and Scope of Immunotherapy Drugs for Neuroblastoma
1.2 Immunotherapy Drugs for Neuroblastoma Segment by Type
1.2.1 Global Immunotherapy Drugs for Neuroblastoma Market Value Comparison by Type (2024-2034)
1.2.2 Dinutuximab
1.2.3 Naxitamab
1.2.4 Other
1.3 Immunotherapy Drugs for Neuroblastoma Segment by Application
1.3.1 Global Immunotherapy Drugs for Neuroblastoma Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Immunotherapy Drugs for Neuroblastoma Market Size Estimates and Forecasts
1.4.1 Global Immunotherapy Drugs for Neuroblastoma Revenue 2018-2034
1.4.2 Global Immunotherapy Drugs for Neuroblastoma Sales 2018-2034
1.4.3 Global Immunotherapy Drugs for Neuroblastoma Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Immunotherapy Drugs for Neuroblastoma Market Competition by Manufacturers
2.1 Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Manufacturers (2018-2023)
2.2 Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Manufacturers (2018-2023)
2.4 Global Immunotherapy Drugs for Neuroblastoma Industry Ranking 2021 VS 2024 VS 2023
2.5 Global Key Manufacturers of Immunotherapy Drugs for Neuroblastoma, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Immunotherapy Drugs for Neuroblastoma, Product Type & Application
2.7 Immunotherapy Drugs for Neuroblastoma Market Competitive Situation and Trends
2.7.1 Immunotherapy Drugs for Neuroblastoma Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Immunotherapy Drugs for Neuroblastoma Players Market Share by Revenue
2.7.3 Global Immunotherapy Drugs for Neuroblastoma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Immunotherapy Drugs for Neuroblastoma Retrospective Market Scenario by Region
3.1 Global Immunotherapy Drugs for Neuroblastoma Market Size by Region: 2018 Versus 2024 Versus 2034
3.2 Global Immunotherapy Drugs for Neuroblastoma Global Immunotherapy Drugs for Neuroblastoma Sales by Region: 2018-2034
3.2.1 Global Immunotherapy Drugs for Neuroblastoma Sales by Region: 2018-2023
3.2.2 Global Immunotherapy Drugs for Neuroblastoma Sales by Region: 2024-2034
3.3 Global Immunotherapy Drugs for Neuroblastoma Global Immunotherapy Drugs for Neuroblastoma Revenue by Region: 2018-2034
3.3.1 Global Immunotherapy Drugs for Neuroblastoma Revenue by Region: 2018-2023
3.3.2 Global Immunotherapy Drugs for Neuroblastoma Revenue by Region: 2024-2034
3.4 North America Immunotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.4.1 North America Immunotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2024 VS 2034
3.4.2 North America Immunotherapy Drugs for Neuroblastoma Sales by Country (2018-2034)
3.4.3 North America Immunotherapy Drugs for Neuroblastoma Revenue by Country (2018-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Immunotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.5.1 Europe Immunotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2024 VS 2034
3.5.2 Europe Immunotherapy Drugs for Neuroblastoma Sales by Country (2018-2034)
3.5.3 Europe Immunotherapy Drugs for Neuroblastoma Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Immunotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.6.1 Asia Pacific Immunotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2024 VS 2034
3.6.2 Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales by Country (2018-2034)
3.6.3 Asia Pacific Immunotherapy Drugs for Neuroblastoma Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Immunotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.7.1 Latin America Immunotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2024 VS 2034
3.7.2 Latin America Immunotherapy Drugs for Neuroblastoma Sales by Country (2018-2034)
3.7.3 Latin America Immunotherapy Drugs for Neuroblastoma Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.8.1 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2024 VS 2034
3.8.2 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Sales by Country (2018-2034)
3.8.3 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Immunotherapy Drugs for Neuroblastoma Sales by Type (2018-2034)
4.1.1 Global Immunotherapy Drugs for Neuroblastoma Sales by Type (2018-2023)
4.1.2 Global Immunotherapy Drugs for Neuroblastoma Sales by Type (2024-2034)
4.1.3 Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2018-2034)
4.2 Global Immunotherapy Drugs for Neuroblastoma Revenue by Type (2018-2034)
4.2.1 Global Immunotherapy Drugs for Neuroblastoma Revenue by Type (2018-2023)
4.2.2 Global Immunotherapy Drugs for Neuroblastoma Revenue by Type (2024-2034)
4.2.3 Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2018-2034)
4.3 Global Immunotherapy Drugs for Neuroblastoma Price by Type (2018-2034)
5 Segment by Application
5.1 Global Immunotherapy Drugs for Neuroblastoma Sales by Application (2018-2034)
5.1.1 Global Immunotherapy Drugs for Neuroblastoma Sales by Application (2018-2023)
5.1.2 Global Immunotherapy Drugs for Neuroblastoma Sales by Application (2024-2034)
5.1.3 Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2018-2034)
5.2 Global Immunotherapy Drugs for Neuroblastoma Revenue by Application (2018-2034)
5.2.1 Global Immunotherapy Drugs for Neuroblastoma Revenue by Application (2018-2023)
5.2.2 Global Immunotherapy Drugs for Neuroblastoma Revenue by Application (2024-2034)
5.2.3 Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Application (2018-2034)
5.3 Global Immunotherapy Drugs for Neuroblastoma Price by Application (2018-2034)
6 Key Companies Profiled
6.1 United Therapeutics
6.1.1 United Therapeutics Corporation Information
6.1.2 United Therapeutics Description and Business Overview
6.1.3 United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.1.4 United Therapeutics Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.1.5 United Therapeutics Recent Developments/Updates
6.2 Y-mAbs Therapeutics
6.2.1 Y-mAbs Therapeutics Corporation Information
6.2.2 Y-mAbs Therapeutics Description and Business Overview
6.2.3 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.2.5 Y-mAbs Therapeutics Recent Developments/Updates
6.3 EUSA Pharma
6.3.1 EUSA Pharma Corporation Information
6.3.2 EUSA Pharma Description and Business Overview
6.3.3 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.3.4 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.3.5 EUSA Pharma Recent Developments/Updates
6.4 ANI Pharmaceuticals
6.4.1 ANI Pharmaceuticals Corporation Information
6.4.2 ANI Pharmaceuticals Description and Business Overview
6.4.3 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.4.4 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.4.5 ANI Pharmaceuticals Recent Developments/Updates
6.5 Baxter Healthcare
6.5.1 Baxter Healthcare Corporation Information
6.5.2 Baxter Healthcare Description and Business Overview
6.5.3 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.5.5 Baxter Healthcare Recent Developments/Updates
6.6 Ingenus Pharmaceuticals
6.6.1 Ingenus Pharmaceuticals Corporation Information
6.6.2 Ingenus Pharmaceuticals Description and Business Overview
6.6.3 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Hikma Pharmaceuticals
6.8.1 Hikma Pharmaceuticals Corporation Information
6.8.2 Hikma Pharmaceuticals Description and Business Overview
6.8.3 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.8.5 Hikma Pharmaceuticals Recent Developments/Updates
6.9 Teva Pharmaceuticals
6.9.1 Teva Pharmaceuticals Corporation Information
6.9.2 Teva Pharmaceuticals Description and Business Overview
6.9.3 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product Portfolio
6.9.5 Teva Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Immunotherapy Drugs for Neuroblastoma Industry Chain Analysis
7.2 Immunotherapy Drugs for Neuroblastoma Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Immunotherapy Drugs for Neuroblastoma Production Mode & Process
7.4 Immunotherapy Drugs for Neuroblastoma Sales and Marketing
7.4.1 Immunotherapy Drugs for Neuroblastoma Sales Channels
7.4.2 Immunotherapy Drugs for Neuroblastoma Distributors
7.5 Immunotherapy Drugs for Neuroblastoma Customers
8 Immunotherapy Drugs for Neuroblastoma Market Dynamics
8.1 Immunotherapy Drugs for Neuroblastoma Industry Trends
8.2 Immunotherapy Drugs for Neuroblastoma Market Drivers
8.3 Immunotherapy Drugs for Neuroblastoma Market Challenges
8.4 Immunotherapy Drugs for Neuroblastoma Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Immunotherapy Drugs for Neuroblastoma Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Immunotherapy Drugs for Neuroblastoma Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Immunotherapy Drugs for Neuroblastoma Market Competitive Situation by Manufacturers in 2024
Table 4. Global Immunotherapy Drugs for Neuroblastoma Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Immunotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Immunotherapy Drugs for Neuroblastoma Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Immunotherapy Drugs for Neuroblastoma Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Immunotherapy Drugs for Neuroblastoma, Industry Ranking, 2021 VS 2024 VS 2023
Table 10. Global Key Manufacturers of Immunotherapy Drugs for Neuroblastoma, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Immunotherapy Drugs for Neuroblastoma, Product Type & Application
Table 12. Global Key Manufacturers of Immunotherapy Drugs for Neuroblastoma, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Immunotherapy Drugs for Neuroblastoma by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immunotherapy Drugs for Neuroblastoma as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Immunotherapy Drugs for Neuroblastoma Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 17. Global Immunotherapy Drugs for Neuroblastoma Sales by Region (2018-2023) & (K Units)
Table 18. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region (2018-2023)
Table 19. Global Immunotherapy Drugs for Neuroblastoma Sales by Region (2024-2034) & (K Units)
Table 20. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region (2024-2034)
Table 21. Global Immunotherapy Drugs for Neuroblastoma Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2018-2023)
Table 23. Global Immunotherapy Drugs for Neuroblastoma Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2024-2034)
Table 25. North America Immunotherapy Drugs for Neuroblastoma Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 26. North America Immunotherapy Drugs for Neuroblastoma Sales by Country (2018-2023) & (K Units)
Table 27. North America Immunotherapy Drugs for Neuroblastoma Sales by Country (2024-2034) & (K Units)
Table 28. North America Immunotherapy Drugs for Neuroblastoma Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Immunotherapy Drugs for Neuroblastoma Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Immunotherapy Drugs for Neuroblastoma Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 31. Europe Immunotherapy Drugs for Neuroblastoma Sales by Country (2018-2023) & (K Units)
Table 32. Europe Immunotherapy Drugs for Neuroblastoma Sales by Country (2024-2034) & (K Units)
Table 33. Europe Immunotherapy Drugs for Neuroblastoma Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Immunotherapy Drugs for Neuroblastoma Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Immunotherapy Drugs for Neuroblastoma Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 36. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Immunotherapy Drugs for Neuroblastoma Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Immunotherapy Drugs for Neuroblastoma Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Immunotherapy Drugs for Neuroblastoma Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 41. Latin America Immunotherapy Drugs for Neuroblastoma Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Immunotherapy Drugs for Neuroblastoma Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Immunotherapy Drugs for Neuroblastoma Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Immunotherapy Drugs for Neuroblastoma Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 46. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Immunotherapy Drugs for Neuroblastoma Sales (K Units) by Type (2018-2023)
Table 51. Global Immunotherapy Drugs for Neuroblastoma Sales (K Units) by Type (2024-2034)
Table 52. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2018-2023)
Table 53. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Type (2024-2034)
Table 54. Global Immunotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Immunotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2018-2023)
Table 57. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2024-2034)
Table 58. Global Immunotherapy Drugs for Neuroblastoma Price (US$/Unit) by Type (2018-2023)
Table 59. Global Immunotherapy Drugs for Neuroblastoma Price (US$/Unit) by Type (2024-2034)
Table 60. Global Immunotherapy Drugs for Neuroblastoma Sales (K Units) by Application (2018-2023)
Table 61. Global Immunotherapy Drugs for Neuroblastoma Sales (K Units) by Application (2024-2034)
Table 62. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2018-2023)
Table 63. Global Immunotherapy Drugs for Neuroblastoma Sales Market Share by Application (2024-2034)
Table 64. Global Immunotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Immunotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Application (2018-2023)
Table 67. Global Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Application (2024-2034)
Table 68. Global Immunotherapy Drugs for Neuroblastoma Price (US$/Unit) by Application (2018-2023)
Table 69. Global Immunotherapy Drugs for Neuroblastoma Price (US$/Unit) by Application (2024-2034)
Table 70. United Therapeutics Corporation Information
Table 71. United Therapeutics Description and Business Overview
Table 72. United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. United Therapeutics Immunotherapy Drugs for Neuroblastoma Product
Table 74. United Therapeutics Recent Developments/Updates
Table 75. Y-mAbs Therapeutics Corporation Information
Table 76. Y-mAbs Therapeutics Description and Business Overview
Table 77. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product
Table 79. Y-mAbs Therapeutics Recent Developments/Updates
Table 80. EUSA Pharma Corporation Information
Table 81. EUSA Pharma Description and Business Overview
Table 82. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product
Table 84. EUSA Pharma Recent Developments/Updates
Table 85. ANI Pharmaceuticals Corporation Information
Table 86. ANI Pharmaceuticals Description and Business Overview
Table 87. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product
Table 89. ANI Pharmaceuticals Recent Developments/Updates
Table 90. Baxter Healthcare Corporation Information
Table 91. Baxter Healthcare Description and Business Overview
Table 92. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product
Table 94. Baxter Healthcare Recent Developments/Updates
Table 95. Ingenus Pharmaceuticals Corporation Information
Table 96. Ingenus Pharmaceuticals Description and Business Overview
Table 97. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product
Table 99. Ingenus Pharmaceuticals Recent Developments/Updates
Table 100. Pfizer Corporation Information
Table 101. Pfizer Description and Business Overview
Table 102. Pfizer Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Pfizer Immunotherapy Drugs for Neuroblastoma Product
Table 104. Pfizer Recent Developments/Updates
Table 105. Hikma Pharmaceuticals Corporation Information
Table 106. Hikma Pharmaceuticals Description and Business Overview
Table 107. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product
Table 109. Hikma Pharmaceuticals Recent Developments/Updates
Table 110. Teva Pharmaceuticals Corporation Information
Table 111. Teva Pharmaceuticals Description and Business Overview
Table 112. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product
Table 114. Teva Pharmaceuticals Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Immunotherapy Drugs for Neuroblastoma Distributors List
Table 118. Immunotherapy Drugs for Neuroblastoma Customers List
Table 119. Immunotherapy Drugs for Neuroblastoma Market Trends
Table 120. Immunotherapy Drugs for Neuroblastoma Market Drivers
Table 121. Immunotherapy Drugs for Neuroblastoma Market Challenges
Table 122. Immunotherapy Drugs for Neuroblastoma Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Immunotherapy Drugs for Neuroblastoma
Figure 2. Global Immunotherapy Drugs for Neuroblastoma Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Immunotherapy Drugs for Neuroblastoma Market Share by Type in 2024 & 2034
Figure 4. Dinutuximab Product Picture
Figure 5. Naxitamab Product Picture
Figure 6. Other Product Picture
Figure 7. Global Immunotherapy Drugs for Neuroblastoma Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 8. Global Immunotherapy Drugs for Neuroblastoma Market Share by Application in 2024 & 2034
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Other
Figure 12. Global Immunotherapy Drugs for Neuroblastoma Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 13. Global Immunotherapy Drugs for Neuroblastoma Market Size (2018-2034) & (US$ Million)
Figure 14. Global Immunotherapy Drugs for Neuroblastoma Sales (2018-2034) & (K Units)
Figure 15. Global Immunotherapy Drugs for Neuroblastoma Average Price (US$/Unit) & (2018-2034)
Figure 16. Immunotherapy Drugs for Neuroblastoma Report Years Considered
Figure 17. Immunotherapy Drugs for Neuroblastoma Sales Share by Manufacturers in 2024
Figure 18. Global Immunotherapy Drugs for Neuroblastoma Revenue Share by Manufacturers in 2024
Figure 19. The Global 5 and 10 Largest Immunotherapy Drugs for Neuroblastoma Players: Market Share by Revenue in 2024
Figure 20. Immunotherapy Drugs for Neuroblastoma Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2024
Figure 21. Global Immunotherapy Drugs for Neuroblastoma Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Figure 22. North America Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country (2018-2034)
Figure 23. North America Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2018-2034)
Figure 24. United States Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 25. Canada Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 26. Europe Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country (2018-2034)
Figure 27. Europe Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2018-2034)
Figure 28. Germany Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 29. France Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 30. U.K. Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. Italy Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. Russia Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. Asia Pacific Immunotherapy Drugs for Neuroblastoma Sales Market Share by Region (2018-2034)
Figure 34. Asia Pacific Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2018-2034)
Figure 35. China Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 36. Japan Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. South Korea Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. India Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. Australia Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. China Taiwan Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. Southeast Asia Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Latin America Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country (2018-2034)
Figure 43. Latin America Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2018-2034)
Figure 44. Mexico Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Brazil Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Argentina Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 47. Colombia Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 48. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Market Share by Country (2018-2034)
Figure 49. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2018-2034)
Figure 50. Turkey Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 51. Saudi Arabia Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 52. UAE Immunotherapy Drugs for Neuroblastoma Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 53. Global Sales Market Share of Immunotherapy Drugs for Neuroblastoma by Type (2018-2034)
Figure 54. Global Revenue Market Share of Immunotherapy Drugs for Neuroblastoma by Type (2018-2034)
Figure 55. Global Immunotherapy Drugs for Neuroblastoma Price (US$/Unit) by Type (2018-2034)
Figure 56. Global Sales Market Share of Immunotherapy Drugs for Neuroblastoma by Application (2018-2034)
Figure 57. Global Revenue Market Share of Immunotherapy Drugs for Neuroblastoma by Application (2018-2034)
Figure 58. Global Immunotherapy Drugs for Neuroblastoma Price (US$/Unit) by Application (2018-2034)
Figure 59. Immunotherapy Drugs for Neuroblastoma Value Chain
Figure 60. Immunotherapy Drugs for Neuroblastoma Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed